HEALTH products maker Johnson & Johnson's profit rose 9-per cent in the third quarter on strong sales of its prescription drugs and of consumer products overseas. The New Jersey-based maker of contraceptives, contact lenses and baby products yesterday reported net income of dollars-2.76bn (GBP1.48bn) for the July to September period, up from dollars-2.54bn in the year-ago quarter. Revenues totalled dollars-13.3bn, up 8-per cent from dollars-12.3bn in the third quarter of 2005. Sales of prescription drugs rose 8-per cent overall and 9-per cent in the United States. They were led by a 16-per cent increase in sales of the antipsychotic drug Risperdal to dollars-1.07bn, and a 74-per cent jump in foreign sales of Remicade for rheumatoid arthritis and other immune disorders for a total of dollars-776m. - AP